Literature DB >> 22180408

New drugs for ovarian cancer.

K Bell-McGuinn1, J Konner, W Tew, D R Spriggs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22180408     DOI： 10.1093/annonc/mdr531

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.

Authors:  Carlotta Defferrari; Sara Campora; Mauro D'Amico; Arnoldo Piccardo; Ennio Biscaldi; Daniela Rosselli; Ambra Pasa; Matteo Puntoni; Alberto Gozza; Alessandra Gennari; Silvia Zanardi; Rita Lionetto; Michela Bandelloni; Andrea Decensi
Journal:  J Ovarian Res       Date:  2012-06-25       Impact factor: 4.234

2.  Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.

Authors:  Max J Cotler; Khalil B Ramadi; Xiaonan Hou; Elena Christodoulopoulos; Sebastian Ahn; Ashvin Bashyam; Huiming Ding; Melissa Larson; Ann L Oberg; Charles Whittaker; Oliver Jonas; Scott H Kaufmann; S John Weroha; Michael J Cima
Journal:  Transl Oncol       Date:  2022-04-26       Impact factor: 4.803

3.  The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Authors:  Merete Thune Wiiger; Hemaseh Bideli; Oystein Fodstad; Kjersti Flatmark; Yvonne Andersson
Journal:  J Ovarian Res       Date:  2014-02-15       Impact factor: 4.234

4.  Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.

Authors:  Marek Malecki; Jessica Dahlke; Melissa Haig; Lynn Wohlwend; Raf Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.